Although it was shown that p-nitrophenol is anti-androgenic in vivo, the molecular details of how p-nitrophenol inhibits AR signaling are still not quite clear. In this report, we want to figure out this signaling in human cells. Methods: (I) Cell viability assay; (II) endogenous expression of androgen-activated genes; (III) expression, and purification of the FK1 domain of FKBP51; (IV) fluorescence quenching assay; (V) crystallization and data collection; (VI) structure determination; (VII) molecular dynamics (MD) simulation; (VIII) the free energy calculation. Results: we show that p-nitrophenol inhibits the androgen dependent cell growth and down-regulates the expression levels of AR target genes. Furthermore, we identified that p-nitrophenol binds with micromolar affinity to the Hsp90 co-chaperone FKBP51, a protein essential for AR activation. Crystal structure of FKBP51 in complex with p-nitrophenol revealed that p-nitrophenol occupies a hydrophobic pocket of FKBP51 that is vital for AR activity enhancement. Molecular dynamics simulation indicate that p-nitrophenol is stably bound to the FKBP51 pocket and the hotspot residues that involved p-nitrophenol binding are mainly hydrophobic and overlap with the AR interaction site.
binding mechanism between p-nitrophenol and its potential molecular target FKBP51, providing guidelines for assessing the long term health risks of p-nitrophenol and its derivatives. Objective: Although it is well known that apoptosis contributes to cancer cell death, the role of autophagy in cancer cell death has remained in dispute. Atorvastatin has been suggested to exhibit anti-cancer effects. The present study aimed to examine atorvastatin-induced autophagyassociated cell death and the autophagy-associated gene expression profile in the PC3 prostate carcinoma cell line. Methods: The atorvastatin-induced process of autophagy in PC3 cells was determined via evaluation of the cellular expression levels of autophagosomal marker light-chain-3 (LC3)-II, using immunoblotting and counting of green fluorescent protein (GFP)-LC3-transfected autophagiccells. Apoptosis was examined by terminal deoxynucleotidyl transferase dUTP nick end labeling assay and an MTT assay was used to evaluate cell viability. Total RNA of PC3 cells was isolated for characterization of the gene expression Transl Androl Urol, 2016;5(S1) tau.amegroups.com profile following atorvastatin treatment. Results: Atorvastatin treatment of PC3 cells for 24 h increased the expression of GFP-LC3-II by >25% and expression continued for >72 h, while apoptosis was not significantly induced within this time period. Four genes associated with the autophagy machinery were also significantly upregulated. Conclusions: In the presence of atorvastatin, autophagy may be unable to abrogate cell damage and may therefore contribute to cellular dysfunction, leading to autophagic/ type II programmed cell death. In response to atorvastatin treatment, the expression of genes involved in autophagic mediating pathways may have a role in tumor suppression. Objective: To evaluate whether the single nucleotide polymorphism (SNP), rs1805415 in the PARP1 gene impact alone or in combination on overall survival (OS) in patients with bladder cancer of Gansu province. Methods: The association between PARP1 genetic polymorphisms and clinicopathologic characteristics of 144 patients with BC was analyzed using QuantStudio™ 12K Flex Real-Time PCR System clamping. Results: The PARP1 genotype had a notable impact on OS. Kaplan-Meier analysis estimates a decreasing OS (P=0.020) between CC, CT and TT genotype patients, survival curves were calculated for overall according to the PARP1 genotypes and between C-allele and T-allele. However, patients with TT genotype had significantly shorter survival time compared with the (CT + CC) genotype patients. In multivariate analysis, revealed that pathological classification (HR 4.183, P=0.025) , smoking status (HR 6.202, P=0.048) and recurrence (HR 32.529, P=0.003) were found to be a strong independent prognosticator with marked increased risk for poor OS in different genotype. Despite the close correlation between PARP1-SNP and survival in univariate analysis, there was no significant difference in the probabilities of overall survival between the genotypes (P=0.832) in this study cohort. Conclusions: Analysis of genotypes and clinical data for bladder cancer patients indicates that the PARP1 rs1805415 genotype may be a useful prognostic genetic marker for bladder cancer. 
